Vanguard Group
ELDN icon

Vanguard Group’s Eledon Pharmaceuticals ELDN Stock Holding History

Vanguard Group’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$6.1M Buy
4,039,686
+771,903
+24% +$1.83M ﹤0.01% 3175
2025
Q3 		$8.46M Sell
3,267,783
-50,600
-2% -$148K ﹤0.01% 3057
2025
Q2 		$8.99M Buy
3,318,383
+365,256
+12% +$1.1M ﹤0.01% 2959
2025
Q1 		$10M Buy
2,953,127
+58,488
+2% +$241K ﹤0.01% 2846
2024
Q4 		$11.9M Buy
2,894,639
+1,329,152
+85% +$5.24M ﹤0.01% 2859
2024
Q3 		$3.9M Buy
1,565,487
+461,092
+42% +$1.23M ﹤0.01% 3363
2024
Q2 		$2.92M Buy
1,104,395
+135,274
+14% +$323K ﹤0.01% 3450
2024
Q1 		$2M Buy
969,121
+273,703
+39% +$488K ﹤0.01% 3594
2023
Q4 		$1.25M Buy
695,418
+20,898
+3% +$29K ﹤0.01% 3750
2023
Q3 		$924K Sell
674,520
-5,037
-0.7% -$6.72K ﹤0.01% 3864
2023
Q2 		$931K Hold
679,557
– – ﹤0.01% 3925
2023
Q1 		$1.6M Hold
679,557
– – ﹤0.01% 3753
2022
Q4 		$1.55M Buy
679,557
+314
+0% +$776 ﹤0.01% 3761
2022
Q3 		$1.88M Hold
679,243
– – ﹤0.01% 3770
2022
Q2 		$1.66M Hold
679,243
– – ﹤0.01% 3885
2022
Q1 		$2.68M Buy
679,243
+9,543
+1% +$37K ﹤0.01% 3833
2021
Q4 		$2.95M Sell
669,700
-813
-0.1% -$4.11K ﹤0.01% 3876
2021
Q3 		$4.14M Buy
670,513
+460,763
+220% +$3.22M ﹤0.01% 3775
2021
Q2 		$1.66M Sell
209,750
-20,294
-9% -$191K ﹤0.01% 4019
2021
Q1 		$2.46M Buy
230,044
+226,001
+5,590% +$3.41M ﹤0.01% 3818
2020
Q4 		$62K Buy
4,043
+999
+33% +$19.1K ﹤0.01% 4171
2020
Q3 		$52K Hold
3,044
– – ﹤0.01% 4064
2020
Q2 		$25K Buy
3,044
+950
+45% +$10.7K ﹤0.01% 4055
2020
Q1 		$15K Hold
2,094
– – ﹤0.01% 4057
2019
Q4 		$22K Sell
2,094
-1,393
-40% -$14.8K ﹤0.01% 4084
2019
Q3 		$39K Sell
3,487
-11,522
-77% -$166K ﹤0.01% 4097
2019
Q2 		$273K Buy
15,009
+12,620
+528% +$552K ﹤0.01% 3924
2019
Q1 		$173K Buy
2,389
+33
+1% +$2.19K ﹤0.01% 3949
2018
Q4 		$68K Sell
2,356
-5,177
-69% -$330K ﹤0.01% 4045
2018
Q3 		$633K Buy
7,533
+3,191
+73% +$326K ﹤0.01% 3810
2018
Q2 		$547K Buy
4,342
+1,902
+78% +$197K ﹤0.01% 3809
2018
Q1 		$212K Buy
2,440
+24
+1% +$1.77K ﹤0.01% 3944
2017
Q4 		$168K Sell
2,416
-88
-4% -$6.65K ﹤0.01% 3953
2017
Q3 		$235K Buy
2,504
+126
+5% +$10.5K ﹤0.01% 3884
2017
Q2 		$251K Sell
2,378
-152
-6% -$15.5K ﹤0.01% 3860
2017
Q1 		$343K Buy
2,530
+466
+23% +$68.5K ﹤0.01% 3813
2016
Q4 		$327K Buy
2,064
+1,376
+200% +$264K ﹤0.01% 3811
2016
Q3 		$171K Sell
688
-896
-57% -$328K ﹤0.01% 3924
2016
Q2 		$1.41M Buy
1,584
+44
+3% +$48.5K ﹤0.01% 3499
2016
Q1 		$1.4M Buy
1,540
+56
+4% +$55K ﹤0.01% 3493
2015
Q4 		$2.1M Buy
1,484
+65
+5% +$113K ﹤0.01% 3379
2015
Q3 		$2.38M Buy
1,419
+174
+14% +$358K ﹤0.01% 3294
2015
Q2 		$2.68M Buy
1,245
+62
+5% +$120K ﹤0.01% 3297
2015
Q1 		$2.17M Buy
1,183
+205
+21% +$452K ﹤0.01% 3374
2014
Q4 		$2.33M Buy
+978
New +$2.32M ﹤0.01% 3229

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group's ELDN Position: Q4 2025 in Review

Vanguard Group increased its Eledon Pharmaceuticals (ELDN) stake by 24% in Q4 2025, buying an estimated $1.83M and bringing the position to 4,039,686 shares worth $6.1M. The position accounts for ﹤0.01% of the portfolio, ranked #3175.

Vanguard Group first reported a position in ELDN in Q4 2014 and has held it in 45 quarters since. The position peaked at $11.9M in Q4 2024. 95 funds tracked by Wall St. Rank hold ELDN as of Q4 2025.

  • Vanguard Group held 4,039,686 shares of Eledon Pharmaceuticals worth $6.1M as of Q4 2025.
  • Vanguard Group bought 771,903 Eledon Pharmaceuticals shares in Q4 2025, an estimated $1.83M.
  • Eledon Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3175 holding.
  • Vanguard Group first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 45 quarters since.
  • Vanguard Group's Eledon Pharmaceuticals position peaked at $11.9M in Q4 2024.
  • 95 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.